Étienne Girard
Prenetics Global (NASDAQ: PRE), a health sciences company, has raised $48 million in an oversubscribed equity round, signaling strong investor confidence in its Bitcoin treasury strategy and the continued growth of its wellness brand IM8.
According to Monday’s announcement, the round saw participation from leading crypto-focused investors, including Kraken, Exodus, GPTX (founded by Jihan Wu), DL Holdings, and American Ventures.
Prominent backers such as tennis champion Aryna Sabalenka and Hong Kong billionaire Adrian Cheng also increased their stakes in the firm. Prenetics’ existing shareholder base includes global icons like David Beckham, further underscoring the company’s strong brand positioning.
The company expects the round to generate gross proceeds of $48 million, which could increase to $216 million if all associated warrants are exercised.
Strengthening Bitcoin Treasury and Global Expansion
Prenetics CEO Danny Yeung stated that the capital infusion will help the company accelerate IM8’s international expansion while reinforcing its Bitcoin-focused treasury strategy.
In June 2025, Prenetics unveiled its Bitcoin treasury initiative, beginning a “daily 1 BTC accumulation” program on August 1. As of October 27, the company holds approximately 275 BTC, valued at around $31 million. Following this funding round, Prenetics expects to maintain total liquidity of roughly $131 million.
IM8: The Rapidly Growing Supplement Brand
IM8, co-founded by David Beckham, has quickly become one of Prenetics’ most successful ventures. The brand generated $100 million in recurring revenue within just 11 months of its launch. Prenetics projects IM8’s revenue to reach $160–200 million by 2026, driven by strong demand for health and performance-focused supplements.
“Our long-term ambition is bold but achievable — to reach $1 billion in annual revenue and $1 billion in Bitcoin holdings within five years,” said Yeung, highlighting the company’s dual focus on digital assets and consumer health innovation.
Market Performance
Despite the positive funding news, Prenetics’ stock fell 21.96% on Monday to $13.08, before rebounding 4.51% in after-hours trading, according to Yahoo Finance. Over the past six months, shares have surged 161.6%, reflecting growing investor optimism about the firm’s evolving business model.
